Influence of Lisdexamfetamine Mesilate (Vyas) in the treatment of premature ejaculation

Influence of Lisdexamfetamine Mesilate (Vyas) in the treatment of premature ejaculation: A double-blind randomized clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160523028008N10

Enrollment

Registered

2021-02-08

Start date

2021-03-05

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ejaculation. Premature ejaculation

Interventions

Intervention 1: Intervention group: 30 mg capsule of Lisdexamfetamine Mesilate (Vyas). Intervention 2: Control group: Placebo tablets.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age older and equal to 18 yearse Married and having at least 6 months of continuous sexual intercourse with a sexual partner Clinical diagnosis of premature ejaculation (PE) based on premature ejaculation diagnosis test( PEDT)

Exclusion criteria

Exclusion criteria: Taking drugs for sexual disorders during the study2 Having depression or other major psychiatric disorders during the study

Design outcomes

Primary

Measure	Time frame
Ejaculation Time. Timepoint: After every intercourse. Method of measurement: By the timer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Haghighi

Hamedan University of Medical Sciences

haghighi@umsha.ac.ir+98 81 1828 5015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026